CR20190433A - Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 - Google Patents
Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1Info
- Publication number
- CR20190433A CR20190433A CR20190433A CR20190433A CR20190433A CR 20190433 A CR20190433 A CR 20190433A CR 20190433 A CR20190433 A CR 20190433A CR 20190433 A CR20190433 A CR 20190433A CR 20190433 A CR20190433 A CR 20190433A
- Authority
- CR
- Costa Rica
- Prior art keywords
- ire1
- que
- describen
- pyridyloxy
- con
- Prior art date
Links
- -1 Pyrimidinyl-pyridyloxy-naphthyl compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101100452784 Caenorhabditis elegans ire-1 gene Proteins 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 102100030013 Endoribonuclease Human genes 0.000 abstract 5
- 108091006081 Inositol-requiring enzyme-1 Proteins 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 abstract 1
- 229960000367 inositol Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017077059 | 2017-03-17 | ||
| PCT/CN2018/079292 WO2018166528A1 (en) | 2017-03-17 | 2018-03-16 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190433A true CR20190433A (es) | 2019-11-20 |
Family
ID=63522807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190433A CR20190433A (es) | 2017-03-17 | 2018-03-16 | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10968203B2 (es) |
| EP (1) | EP3596063A4 (es) |
| JP (1) | JP6925435B2 (es) |
| KR (1) | KR20190141145A (es) |
| CN (1) | CN111247136A (es) |
| AR (1) | AR111281A1 (es) |
| AU (1) | AU2018233402A1 (es) |
| BR (1) | BR112019019193A2 (es) |
| CA (1) | CA3056833A1 (es) |
| CL (1) | CL2019002671A1 (es) |
| CO (1) | CO2019010078A2 (es) |
| CR (1) | CR20190433A (es) |
| IL (1) | IL269302A (es) |
| PE (1) | PE20191557A1 (es) |
| SG (1) | SG11201908517XA (es) |
| TW (1) | TW201838981A (es) |
| WO (1) | WO2018166528A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2762833C2 (ru) | 2017-03-17 | 2021-12-23 | Мейдзи Сейка Фарма Ко., Лтд. | Средство для борьбы с болезнями растений |
| AU2018278311B2 (en) | 2017-06-01 | 2021-10-07 | Cornell University | IRE1 small molecule inhibitors |
| US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
| WO2020047518A1 (en) * | 2018-08-30 | 2020-03-05 | The Regents Of The University Of California | Ire1 kinase inhibitors and uses thereof |
| CN112689528B (zh) * | 2018-09-12 | 2024-05-14 | 基因泰克公司 | 嘧啶基-杂芳氧基-萘基化合物和使用方法 |
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| WO2020117634A1 (en) * | 2018-12-03 | 2020-06-11 | Cornell University | Ire1 small molecule inhibitors |
| JP7546299B2 (ja) * | 2018-12-03 | 2024-09-06 | コーネル・ユニバーシティー | Ｉｒｅ１小分子阻害物質 |
| WO2020142612A1 (en) | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
| US12479818B2 (en) | 2019-05-15 | 2025-11-25 | Cornell University | Treatment of fibrosis with IRE1 small molecule inhibitors |
| CA3188602A1 (en) * | 2020-08-07 | 2022-02-10 | Richard Keenan | Pyrazolopyridine compounds and methods of inhibiting ire1 using same |
| CN116710429A (zh) * | 2020-11-13 | 2023-09-05 | 加利福尼亚大学董事会 | IRE1α抑制剂及其用途 |
| KR20230118855A (ko) * | 2020-11-13 | 2023-08-14 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | IRE1α 억제제 및 이의 용도 |
| CN114907350B (zh) * | 2021-02-10 | 2023-12-29 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物、制备方法和用途 |
| CN116693357B (zh) * | 2023-06-07 | 2026-01-27 | 西安工程大学 | 一种β-三氟甲基不饱和酰胺及其合成方法 |
| WO2026136623A1 (en) | 2024-12-19 | 2026-06-25 | Genentech, Inc. | Ire1 degrader compounds and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1751136B1 (en) | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| CN104230901A (zh) | 2008-09-15 | 2014-12-24 | 加利福尼亚大学董事会 | 用于调节ire1、src和abl活性的方法和组合物 |
| ES2638317T3 (es) | 2013-04-04 | 2017-10-19 | Janssen Pharmaceutica Nv | Nuevos derivados de N-(2,3-dihidro-1H-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina y N-(2,3-dihidro-1H-indol-5-il)-4-quinazolinamina como inhibidores de PERK |
-
2018
- 2018-03-15 TW TW107108924A patent/TW201838981A/zh unknown
- 2018-03-15 AR ARP180100604A patent/AR111281A1/es unknown
- 2018-03-16 AU AU2018233402A patent/AU2018233402A1/en not_active Abandoned
- 2018-03-16 JP JP2019551376A patent/JP6925435B2/ja active Active
- 2018-03-16 CN CN201880032314.6A patent/CN111247136A/zh active Pending
- 2018-03-16 BR BR112019019193A patent/BR112019019193A2/pt not_active Application Discontinuation
- 2018-03-16 EP EP18768363.6A patent/EP3596063A4/en active Pending
- 2018-03-16 CA CA3056833A patent/CA3056833A1/en not_active Abandoned
- 2018-03-16 PE PE2019001893A patent/PE20191557A1/es unknown
- 2018-03-16 WO PCT/CN2018/079292 patent/WO2018166528A1/en not_active Ceased
- 2018-03-16 CR CR20190433A patent/CR20190433A/es unknown
- 2018-03-16 KR KR1020197030386A patent/KR20190141145A/ko not_active Ceased
- 2018-03-16 SG SG11201908517X patent/SG11201908517XA/en unknown
- 2018-05-24 US US15/989,008 patent/US10968203B2/en active Active
-
2019
- 2019-09-12 IL IL26930219A patent/IL269302A/en unknown
- 2019-09-17 CL CL2019002671A patent/CL2019002671A1/es unknown
- 2019-09-18 CO CONC2019/0010078A patent/CO2019010078A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201838981A (zh) | 2018-11-01 |
| CO2019010078A2 (es) | 2020-01-17 |
| IL269302A (en) | 2019-11-28 |
| US20180265497A1 (en) | 2018-09-20 |
| BR112019019193A2 (pt) | 2020-04-22 |
| CL2019002671A1 (es) | 2019-12-06 |
| PE20191557A1 (es) | 2019-10-24 |
| JP6925435B2 (ja) | 2021-08-25 |
| CN111247136A (zh) | 2020-06-05 |
| EP3596063A4 (en) | 2020-12-30 |
| EP3596063A1 (en) | 2020-01-22 |
| AU2018233402A1 (en) | 2019-10-10 |
| SG11201908517XA (en) | 2019-10-30 |
| KR20190141145A (ko) | 2019-12-23 |
| JP2020514377A (ja) | 2020-05-21 |
| WO2018166528A1 (en) | 2018-09-20 |
| US10968203B2 (en) | 2021-04-06 |
| CA3056833A1 (en) | 2018-09-20 |
| AR111281A1 (es) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| MX2017007489A (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. | |
| ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX2020007731A (es) | Compuestos moduladores de receptor de estrogeno. | |
| UY37098A (es) | Moduladores de ror-gamma | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| MX388786B (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
| MX383650B (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| MX385336B (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| MX383292B (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
| MX386938B (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| MX2021004586A (es) | Uso de dosis mas altas de formulaciones de huperzina de liberacion modificada. | |
| TN2018000175A1 (en) | Indane derivatives as mglur7 modulators | |
| PH12019502122A1 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| MX2020009645A (es) | Inhibidores de secrecion de proteinas basados en triazaciclododecansulfonamida ("tcd"). | |
| AR122456A2 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos | |
| NZ786543A (en) | Compounds active towards nuclear receptors | |
| AR114282A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”) | |
| AR105921A1 (es) | Compuestos terapéuticos para el dolor y síntesis de estos |